ClinicalTrials.gg
RecruitingNCT07943130EMBRACEUpdated Nov 17, 2026

Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment

An observational study in Maternal Depression, Maternal Anxiety and Preterm Birth Infants, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 24 Weeks to 30 Weeks. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
96
Ages
24 Weeks to 30 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Depression with a site in Italy — 32 open to participants now, 33 under way, 2 of them phase 3. Depression · Italy.

Planned enrollment
21st of 28
96 · median 200
Started
2026
with 2 others
Observational
28 of 102
8 open now
Primary completion
2027-06
later than 22 of 32 live
Registered
102nd of 102
by date
Lead sponsor
3 of 102
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Among the 102 studies in Depression with a site in Italy, this one is the 21st largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, reaches primary completion later than 22 of the 32 other live ones, and was the 102nd registered.

Depression

8,601 studies on the registry are indexed under Depression; 1,735 are open to participants now.

Browse Depression studies →

Open to participants now

32 of the 102 studies in Depression with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger; 206 take children under 18; 314 take healthy volunteers.

This study: 24 Weeks to 30 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Depression with a site in Italy, or all of them as a file.
02

Study summary

Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.

Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.

The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.

This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.

The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.

03

Conditions studied

  • Maternal Depression
  • Maternal Anxiety
  • Preterm Birth Infants
04

Who can participate

Ages eligible
24 Weeks to 30 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born between 24+0 and 30+6 weeks of gestational age (GA);
  • Mothers aged ≥ 18 years with adequate understanding of the Italian language;
  • Signed from parents.

Exclusion criteria

Exclusion Criteria:

  • Parents decline participation;
  • Infants with major congenital anomalies, malformations, or genetic syndromes;
  • Mothers with obvious psychiatric conditions, cognitive deficits, or active substance abuse at the time of delivery.
  • Infants birth samples not available (both buccal swab and blood)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
96 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Epigenetic changes on LINE1 (blood samples)

    epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples

    Time frame: up to 48 weeks post menstrual age

  2. Maternal salivary cortisol

    Collected at birth, transition to intermediate care, discharge

    Time frame: up to 12 months corrected age of the infant

Secondary outcomes

  1. Human milk cortisol concentrations

    Collected at birth, transition to intermediate care, discharge

    Time frame: up to 6 months corrected age of the infant

  2. Buccal swab

    Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age

    Time frame: up to 12 months corrected age

  3. Neurological outcome

    Hammersmith neonatal neurological examination performed at NICU discharge

    Time frame: up to 44 weeks post menstrual age

  4. Neonatal Visual Assessment

    Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors.

    Time frame: up to 44 weeks post menstrual age

  5. Neonatal behavior

    Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment

    Time frame: up to 44 weeks post menstrual age

  6. Neurodevelopmental outcome

    Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes.

    Time frame: from 6 to 12 months corrected age

  7. Maternal depression

    Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age.

    Time frame: up to 12 months corrected age of the infant

  8. Maternal stress in the NICU

    Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge.

    Time frame: up to 12 months corrected age of the infant

  9. Maternal bonding

    Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological.

    Time frame: up to 12 months corrected age of the infant

  10. Maternal anxiety and depression

    Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range.

    Time frame: up to 12 months corrected age of the infant

  11. Parenting stress

    Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful)

    Time frame: up to 12 months corrected age of the infant

07

Study locations

1 of 1 sites recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
    Recruiting
    • Camilla Fontana · Contactcamilla.fontana@unimi.it · +390255032951
    • Chiara Bonfanti · Sub investigator
    • Agnese De Carli · Sub investigator
    • Monica Fumagalli · Sub investigator
    • Mary Giorgia Gaccione · Sub investigator
08

References and documents

Publications

  • Casavant SG, Cong X, Moore J, Starkweather A. Associations between preterm infant stress, epigenetic alteration, telomere length and neurodevelopmental outcomes: A systematic review. Early Hum Dev. 2019 Apr;131:63-74. doi: 10.1016/j.earlhumdev.2019.03.003. Epub 2019 Mar 11. PubMed 30870624 ↗
  • Bedrosian TA, Quayle C, Novaresi N, Gage FH. Early life experience drives structural variation of neural genomes in mice. Science. 2018 Mar 23;359(6382):1395-1399. doi: 10.1126/science.aah3378. PubMed 29567711 ↗
  • Rosen-Carole CB, Greenman S, Wang H, Sonawane S, Misra R, O'Connor T, Jarvinen K, D'Angio C, Young BE. Association between maternal stress and premature milk cortisol, milk IgA, and infant health: a cohort study. Front Nutr. 2024 Mar 6;11:1270523. doi: 10.3389/fnut.2024.1270523. eCollection 2024. PubMed 38533463 ↗
  • Fontana C, Marasca F, Provitera L, Mancinelli S, Pesenti N, Sinha S, Passera S, Abrignani S, Mosca F, Lodato S, Bodega B, Fumagalli M. Early maternal care restores LINE-1 methylation and enhances neurodevelopment in preterm infants. BMC Med. 2021 Feb 5;19(1):42. doi: 10.1186/s12916-020-01896-0. PubMed 33541338 ↗
  • Pace CC, Spittle AJ, Molesworth CM, Lee KJ, Northam EA, Cheong JL, Davis PG, Doyle LW, Treyvaud K, Anderson PJ. Evolution of Depression and Anxiety Symptoms in Parents of Very Preterm Infants During the Newborn Period. JAMA Pediatr. 2016 Sep 1;170(9):863-70. doi: 10.1001/jamapediatrics.2016.0810. PubMed 27428766 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 462 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 9 months is below that.

Counting every sponsor, half of 495 studies reached it within 32 months; a quarter within 13 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943130
Collaborators
University of Milan
Responsible party
Camilla Fontana (Dr, University of Milan) — Principal investigator
First posted
Nov 17, 2026
Start date
Aug 25, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Camilla Fontana
Contact
camilla.fontana@unimi.it
0255032951

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion